Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.44 USD
-0.20 (-4.31%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $4.39 -0.05 (-1.13%) 6:46 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 1 - 20 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Surprisingly Strong NASH Biopsy Data ?LiFTs? Prospects; Raise PT to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Litigation Loss Doesn?t Impact Our Projections; Look Forward to August NASH Data and 1H22 Tlando Approval; Reiterate
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Oral T''s NASH Liver Fast Busting Confirmed; Mid-2021 Biopsy Data is the Real Potential Validator; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Tlando De-Risked But Delayed with Tentative Approval; Reiterate Buy Ahead of January Oral-T NASH Liver Fat Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Lipocine Inc.
Industry: Medical - Drugs
Program for Our Fourth Annual Virtual NASH Investor Conference, October 5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Lipocine Inc.
Industry: Medical - Drugs
Tlando PDUFA Imminent; NASH Liver Fat Data by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Lipocine Inc.
Industry: Medical - Drugs
Reviving Tlando Oral TRT With August 28 PDUFA; Raise to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Lipocine Inc.
Industry: Medical - Drugs
After Another CRL, Assume Tlando Is Toast; Shifting Gears Entirely to NASH Story With Mid-2020 Phase 2 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Lipocine Inc.
Industry: Medical - Drugs
One Step Closer to Tlando Approval; November 9 PDUFA; 1Q19 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Tlando Gets Two Approvability Boosts in One Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Oral Testosterone, the Liver Fat Buster? Raise to $5 on Incremental NASH Value Contribution.
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
4Q18 Results; Imminent Tlando Blood Pressure Data Hopefully Gets NDA Back on Track; NASH Story Continues to Evolve
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O